Antibiotic-resistant bacteria have become a rapidly growing threat to public health. Each year, they account for more than 2.8 million infections, according to the U.S. Centers for Disease Control and Prevention.
Biogen is pursuing more dealmaking this year, with plans to spend up to $8B
Biogen appears to be subtly signaling it has a larger appetite for M&A than previously stated. In an exclusive interview with Endpoints News, Biogen head
June 28, 2024